- Poor results for Rigel hepatitis drug Messenger

[Guest guest]

Poor results for Rigel hepatitis drug

Rigel Pharmaceuticals (NASDAQ: RIGL - news) [RIGL] has revealed disappointing

results from its phase I/II clinical study of R803, a novel oral hepatitis C RNA

polymerase inhibitor. Shares fell by four percent in response to the

announcement.

Rigel Pharmaceuticals [RIGL] has revealed disappointing results from its phase

I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor.

Shares fell by four percent in response to the announcement.

http://uk.biz./041123/241/f76by.html

[Guest guest]

Poor results for Rigel hepatitis drug

Rigel Pharmaceuticals (NASDAQ: RIGL - news) [RIGL] has revealed disappointing

results from its phase I/II clinical study of R803, a novel oral hepatitis C RNA

polymerase inhibitor. Shares fell by four percent in response to the

announcement.

Rigel Pharmaceuticals [RIGL] has revealed disappointing results from its phase

I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor.

Shares fell by four percent in response to the announcement.

http://uk.biz./041123/241/f76by.html

[Guest guest]

Poor results for Rigel hepatitis drug

Rigel Pharmaceuticals (NASDAQ: RIGL - news) [RIGL] has revealed disappointing

results from its phase I/II clinical study of R803, a novel oral hepatitis C RNA

polymerase inhibitor. Shares fell by four percent in response to the

announcement.

Rigel Pharmaceuticals [RIGL] has revealed disappointing results from its phase

I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor.

Shares fell by four percent in response to the announcement.

http://uk.biz./041123/241/f76by.html

[Guest guest]

Poor results for Rigel hepatitis drug

Rigel Pharmaceuticals (NASDAQ: RIGL - news) [RIGL] has revealed disappointing

results from its phase I/II clinical study of R803, a novel oral hepatitis C RNA

polymerase inhibitor. Shares fell by four percent in response to the

announcement.

Rigel Pharmaceuticals [RIGL] has revealed disappointing results from its phase

I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor.

Shares fell by four percent in response to the announcement.

http://uk.biz./041123/241/f76by.html